ClinicalTrials.gg
TerminatedNCT03876028Updated Jan 31, 2023

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

A Phase 1 interventional study of Tisagenlecleucel and Ibrutinib in Diffuse Large B-cell Lymphoma, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business reasons

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
25th of 26
10 · median 44
Started
2019
with 3 others
Phase 1
9 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
2 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 25th largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 1, and was the 19th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Lymphoma
  • Diffuse Large B-cell lymphoma
  • DLBCL
  • r/r Diffuse Large B-cell Lymphoma
  • relapsed/refractory DLBCL
  • CTL019
  • Tisagenlecleucel
  • Ibrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed DLBCL as per the local histopathological assessment.
  2. disease having received 2 or more , including anti-CD20 and anthracycline based chemotherapy, and either having progressed after (or relapsed after) , or being ineligible for or not consenting to ASCT.
  3. at time of enrollment.
  4. (ECOG) performance status that is either 0 or 1 at screening.
  5. Adequate renal, liver, and bone marrow, organ function, and minimum level of pulmonary reserve.

Exclusion criteria

Exclusion Criteria:

  1. Patients with Richter's transformation, Burkitt's lymphoma, and primary DLBCL of the CNS.
  2. Prior anti-CD19 directed therapy.
  3. Prior gene therapy.
  4. Prior adoptive T cell therapy.
  5. Prior ibrutinib therapy within the 30 days prior to screening.
  6. Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was > 4 weeks before enrollment.
  7. Prior HSCT
  8. . Significant cardiac abnormality including history of myocardial infarction within 6 months prior to screening as detailed in the study protocol.

Other eligibility criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Ibrutinib (before leukapheresis) + Tisagenlecleucel

    Patients will start ibrutinib treatment before leukapheresis

    Biological: Tisagenlecleucel · Drug: Ibrutinib

  • Experimental
    Ibrutinib (after leukapheresis) + Tisagenlecleucel

    Patients will start ibrutinib treatment after leukapheresis.

    Biological: Tisagenlecleucel · Drug: Ibrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Month 24 is planned study end

    Time frame: 24 months

  2. Severity of adverse events (AEs) and serious adverse events (SAEs)

    Month 24 is planned study end

    Time frame: 24 months

  3. Ibrutinib dose modification following tisagenlecleucel infusion

    Month 24 is planned study end

    Time frame: 24 months

Secondary outcomes

  1. Response Rate

    3-months post tisagenlecleucel infusion, assessed by local investigator according to Lugano criteria

    Time frame: Month 3

  2. Response Rate

    6-month post tisagenlecleucel infusion, assessed by local investigator according to Lugano criteria

    Time frame: Month 6

  3. Overall Response Rate

    Time frame: 24 months

  4. Duration of Response

    Time frame: 24 months

  5. Progression Free Survival (PFS)

    Time frame: 24 months

  6. Overall Survival (OS)

    Time frame: 24 months

  7. Tisagenlecleucel transgene concentrations

    qPCR will be used to measure tisagenlecleucel transgene concentrations in available tissue, such as peripheral blood, bone marrow, tumor/lymph node tissue, and/or CSF.

    Time frame: 24 months

  8. Cellular kinetics of Tisagenlecleucel (Cmax)

    Cmax cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib

    Time frame: 24 months

  9. Cellular kinetics of Tisagenlecleucel (Tmax)

    Tmax cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib

    Time frame: 24 months

  10. Cellular kinetics of Tisagenlecleucel (AUC)

    AUC cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib

    Time frame: 24 months

  11. Cellular kinetics of Tisagenlecleucel (Clast)

    Clast cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib

    Time frame: 24 month

  12. Cellular kinetics of Tisagenlecleucel (Tlast)

    Tlast cellular kinetics parameter (via qPCR) for tisagenlecleucel in the presence of ibrutinib

    Time frame: 24 month

  13. Anti-drug antibody (ADA) response to Tisagenlecleucel (humoral immunogenicity)

    Pre-existing and treatment related immunogenicity (humoral) of tisagenlecleucel will be characterized by flow cytometry

    Time frame: 24 months

  14. Anti- tisagenlecleucel t-cell response (cellular immunogenicity)

    Pre-existing and treatment related immunogenicity (cellular) of tisagenlecleucel will be characterized IFN-g staining and flow cytometry

    Time frame: 24 months

  15. Characterize cellular kinetic parameters in the presence of ADA and/or anti-tisagenlecleucel t-cell response

    Time frame: 24 months

  16. Characterize efficacy of tisagenlecleucel in the presence of ADA and/or anti-tisagenlecleucel t-cell response

    Time frame: 24 month

07

Study locations

2 sites
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2021, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 15, 2019
StartActual
Jun 11, 2019
Primary completionActual
Nov 1, 2021
CompletionActual
Nov 1, 2021
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876028
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Jun 11, 2019
Primary completion
Nov 1, 2021
Completion
Nov 1, 2021
Last update
Jan 31, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tisagenlecleucel · Ibrutinib

Start the discussion